Peptide-based immunotherapeutic approaches to glioma: a review.
Despite advances in surgery, radiation and chemotherapy, the prognosis of patients with malignant glioma is still very poor; therefore, the development of a novel therapeutic modality is essential. There are increasing reports demonstrating that systemic immunotherapy using dendritic cells or a peptide vaccine is capable of inducing an antiglioma response. Peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and prolong survival in patients with glioma without major side effects. Now, peptide-based immunotherapy could be a new treatment modality for patients with brain tumors.
Yamanaka
Ryuya
R
Kurume University School of Medicine, Research Center of Innovative Cancer Therapy, Asahimachi 67, Kurume, Fukuoka 830-0011, Japan. ryaman@med.kurume-u.ac.jp
Itoh
Kyogo
K
D000951:Antigens, Neoplasm / Q000276:immunology*; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D018579:Patient Selection; D016896:Treatment Outcome; D022223:Vaccines, Subunit / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D022223:Vaccines, Subunit